Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682324 · ClinicalTrials.gov registry record · Phase 1
Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07682324 is a Phase 1 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT07682324, a Phase 1 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. Our central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and/or chronicity of neuropathic pain.
Interventions
- OTHER Placebo Control
- DIETARY_SUPPLEMENT Green Tea Leaf Extract Decaffeinated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09-30 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07682324
The ClinicalTrials.gov registry entry for NCT07682324 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Control is the first listed.
NCT07682324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07682324 about?
NCT07682324 is a clinical study titled "Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain". The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. Our central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as lon...
What is the current status of trial NCT07682324?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-09-30. Estimated completion is 2029-03-01.
What interventions are being tested in trial NCT07682324?
The interventions under investigation include: Placebo Control (OTHER), Green Tea Leaf Extract Decaffeinated (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07682324?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.